Skip to content
Monday 17 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
0.00%
CAC 40
8,636.80
0.00%
STOXX 50
6,539.59
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

diabetes

  • Ozempic and Wegovy: What happens when a drug goes viral?

    Wegovy

    Novo Nordisk's Wegovy and Ozempic have been heralded as the solution to the world's growing obesity problems. But when celebrities and influencers misuse them and start documenting their weight loss journeys online, should we take stock?

    Ozempic has boomed in populartity since it was first issued

Trending Articles

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

  • Grandparents fund university degrees to avoid inheritance tax net

  • Aldi boss wades into supermarket ‘price-gouging’ row

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut chatbot goes rogue by charging users to cancel subscription

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook